Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
McKinsey
Deloitte
Queensland Health
Moodys
Chubb
Cerilliant
Johnson and Johnson

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

« Back to Dashboard

Clinical Trials for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Trial ID Title Status Sponsor Phase Summary
NCT00004495 Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis Completed Georgetown University N/A OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 Vitamin Therapy for Prevention of Stroke Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 Homocysteine Study (HOST) Completed Abbott Diagnostics Division Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 Homocysteine Study (HOST) Completed Pan American Laboratories Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 Homocysteine Study (HOST) Completed VA Office of Research and Development Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00053209 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining pemetrexed disodium with gemcitabine may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining pemetrexed disodium with gemcitabine in treating patients who have advanced cancer of the urothelium.
NCT00053209 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed Eastern Cooperative Oncology Group Phase 2 RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining pemetrexed disodium with gemcitabine may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining pemetrexed disodium with gemcitabine in treating patients who have advanced cancer of the urothelium.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Condition Name

Condition Name for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Intervention Trials
End Stage Renal Disease 2
Anaemia 2
Vitamin B12 Deficiency 2
Pulmonary Embolism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Intervention Trials
Vitamin B 12 Deficiency 3
Kidney Failure, Chronic 2
Kidney Diseases 2
Urinary Bladder Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Trials by Country

Trials by Country for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Location Trials
United States 139
India 2
Netherlands 1
Sweden 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Location Trials
Ohio 9
Pennsylvania 8
Illinois 8
Texas 7
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Clinical Trial Phase

Clinical Trial Phase for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 11
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Clinical Trial Phase Trials
Completed 17
Terminated 2
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Sponsor Name

Sponsor Name for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Sponsor Trials
National Cancer Institute (NCI) 8
Gynecologic Oncology Group 4
Eastern Cooperative Oncology Group 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Sponsor Trials
Other 21
NIH 9
Industry 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Dow
Medtronic
Harvard Business School
Federal Trade Commission
Accenture
Cantor Fitzgerald
Cerilliant
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.